GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AXIM Biotechnologies Inc (OTCPK:AXIM) » Definitions » Scaled Net Operating Assets

AXIM (AXIM Biotechnologies) Scaled Net Operating Assets : -0.70 (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is AXIM Biotechnologies Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

AXIM Biotechnologies's operating assets for the quarter that ended in Jun. 2024 was $3.72 Mil. AXIM Biotechnologies's operating liabilities for the quarter that ended in Jun. 2024 was $6.48 Mil. AXIM Biotechnologies's Total Assets for the quarter that ended in Mar. 2024 was $3.94 Mil. Therefore, AXIM Biotechnologies's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2024 was -0.70.


AXIM Biotechnologies Scaled Net Operating Assets Historical Data

The historical data trend for AXIM Biotechnologies's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AXIM Biotechnologies Scaled Net Operating Assets Chart

AXIM Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.16 4.38 0.35 0.15 -0.46

AXIM Biotechnologies Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.02 -0.04 -0.47 -0.21 -0.70

Competitive Comparison of AXIM Biotechnologies's Scaled Net Operating Assets

For the Biotechnology subindustry, AXIM Biotechnologies's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AXIM Biotechnologies's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Scaled Net Operating Assets falls into.



AXIM Biotechnologies Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

AXIM Biotechnologies's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(3.966-5.883)/4.212
=-0.46

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=4.122 - 0.156
=3.966

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=11.778 - 5.8 - 0.095
=5.883

AXIM Biotechnologies's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2024 )
=(Operating Assets (Q: Jun. 2024 )-Operating Liabilities (Q: Jun. 2024 ))/Total Assets (Q: Mar. 2024 )
=(3.722-6.479)/3.935
=-0.70

where

Operating Assets(Q: Jun. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3.728 - 0.006
=3.722

Operating Liabilities(Q: Jun. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=13.262 - 6.69 - 0.093
=6.479

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AXIM Biotechnologies Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of AXIM Biotechnologies's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


AXIM Biotechnologies Business Description

Traded in Other Exchanges
N/A
Address
6191 Cornerstone Court, E, Suite 114, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.
Executives
Kurt Phinney officer: Chief Operating Officer 6914 MAGELLAN WAY, SARASOTA FL 34243
Peter O'rourke director C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001
Catalina Valencia 10 percent owner 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Glycodots, Llc 10 percent owner 6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Juniper & Ivy Corp 10 percent owner 5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007
Huemoeller John Walter Ii director 305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960
Blake Schroeder director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert L Cunningham director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Timothy Richard Scott director 5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert Malasek officer: CFO PO BOX 235472, ENCINITAS CA 92023
Lekhram Changoer 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Medical Marijuana, Inc. 10 percent owner 12255 CROSTHWAITE CIRCLE, POWAY CA 92064
Van Damme Philip A 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Foundation Sanammad 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
George Anastassov 10 percent owner 18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022

AXIM Biotechnologies Headlines

From GuruFocus